Nuvelo and Arca Biopharma announced yesterday that they will be merging to make a late-stage cardiovascular biotechnology company. Nuvelo's alfimeprase, a drug to treat blood clots, failed last year but Nuvelo retained $76 million. This is an example, says Reuters, of failed or failing biotechs being taken over for access to their excess cash.